Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ACT-385781A, Epoprostenol for injection (EFI)
EFI/ACT-385781A · 1 trial · 1 indication
Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT.
Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT.
Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT.
Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT.
Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT.
Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan® to EFI/ACT-385781A and at EOT.
| Arm | Type | Description |
|---|---|---|
| EFI/ACT-385781A | EXPERIMENTAL | EFI/ACT-385781 administered by continuous intravenous infusion via a central venous catheter using an ambulatory infusion pump |
| Name | Type | Description |
|---|---|---|
| EFI/ACT-385781A | DRUG | - |
Inclusion Criteria: 1. Male or female aged 18 years and above 2. Patients with the following types of pulmonary arterial hypertension (PAH) belonging to WHO Group I: Idiopathic (IPAH), Heritable (HPAH), Associated (APAH) with Connective tissue diseases or Drugs and toxins 3. Patients treated with F...
Top 13 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 8 | PHASE3 | Sotatercept, Riociguat, Frespaciguat |
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag, Tyvaso (treprostinil) |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Johnson & Johnson | JNJ | 4 | PHASE3 | selexipag, Macitentan |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606, LIQ861 Treprostinil, LIQ861 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | Levosimendan (TNX-103) |
| Inhibikase Therapeutics, Inc. | IKT | 2 | PHASE3 | IKT-001 |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Tectonic Therapeutic Inc | TECX | 2 | PHASE2 | TX45 |
| Gossamer Bio, Inc. | GOSS | 1 | PHASE3 | Seralutinib |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| GSK plc Sponsored ADR | GSK | 2 | PHASE1 | HS235 |
EFI/ACT-385781A is used for the treatment of pulmonary arterial hypertension (PAH), a type of high blood pressure affecting the arteries in the lungs and the right side of the heart. It is a small molecule developed by Johnson & Johnson and is intended to address this cardiovascular condition.
EFI/ACT-385781A is developed by Johnson & Johnson, a multinational corporation traded on the New York Stock Exchange under the ticker symbol JNJ. The company is responsible for the clinical development of this investigational small molecule for pulmonary arterial hypertension.
EFI/ACT-385781A is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy in patients with pulmonary arterial hypertension.
EFI/ACT-385781A has one completed Phase 3 clinical trial, identified as NCT01431716, titled 'Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension'. This trial enrolled 42 participants across Belgium, Canada, France, Italy, Netherlands, and Spain.
EFI/ACT-385781A is a small molecule, but its specific molecular target has not been disclosed in available information. As such, the exact mechanism of action for this investigational drug in treating pulmonary arterial hypertension is not publicly detailed.